News & Events

Press Releases

Date Title Link
November 7, 2022 Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001 VIEW PDF
May 27, 2022 Aleta Biotherapeutics Announces Presentation at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting VIEW PDF
December 11, 2021 Aleta Biotherapeutics Announces ALETA-001 Poster Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting VIEW PDF
November 9, 2021 Aleta Biotherapeutics Announces ALETA-001 Presentation at 63rd ASH Annual Meeting VIEW PDF
October 1, 2021 Aleta Biotherapeutics to Present at Society for Immunotherapy of Cancer VIEW PDF
June 23, 2021 Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic VIEW PDF
June 21, 2021 Paul Rennert, President & Chief Scientific Officer, Aleta Biotherapeutics will present a talk entitled “A Novel CAR therapy for Metastatic Breast Cancer” at the virtual Her2-Targeted Therapies Summit on Thursday June 24th. This live presentation is scheduled at 9:40am EST. VIEW AGENDA
June 21, 2021 Paul Rennert, President & Chief Scientific Officer, Aleta Biotherapeutics will present a talk entitled “Fusion Proteins to Bridge CAR19 T Cells and Tumor Cells” at the virtual “Next Generation CAR & T Cell Therapies Conference” on Thursday June 24th. This recorded presentation is scheduled at 3:00 EST. VIEW AGENDA
September 1, 2020 CAR T-Cell Optimization Starts in Production, Extends to Therapy VIEW ARTICLE
December 7, 2019 Aleta Biotherapeutics Presents In Vivo Results of a Novel Therapeutic Designed to Reactivate CAR T Cells in Patients Who Relapse After CAR T Therapy VIEW PDF
December 2, 2019 Aleta Biotherapeutics Announces Oral Presentation at the 61st American Society of Hematology Annual Meeting (ASH) VIEW PDF
September 5, 2019 Aleta Biotherapeutics Announces Appointments to Board of Directors VIEW PDF

Media